Oral Capsule Faecal Microbiota Transplantation for CPE Decolonization

Inclusion Criteria: * Admitted as inpatient at the study site at the time of screening. * Aged ≥21 years at the time of screening. * Sufficiently ambulant to return for outpatient clinic study visit. * Detection of CPE (result reported by clinical microbiology laboratory). * Ability to provide informed consent. * Females of childbearing potential who are sexually active with a non-sterilised male partner must agree to use at least one method of effective contraception for the duration of the trial. * Colonisation of the gastrointestinal tract with CPE, confirmed by at least one positive rectal swab taken ≤7 days before randomisation (direct PCR testing using Xpert Carba-R, performed by study team independent of the hospital screening protocol). * Ability to swallow "safety test" capsule (one test capsule given during pre-randomisation evaluation). * Antibiotics ceased for at least 48 hours before pre-randomisation evaluation. * Negative urine pregnancy test for pre-menopausal women taken ≤7 days before randomisation Exclusion Criteria: * Presence of acute diarrhoeal illness (e.g. gastroenteritis, C. difficile colitis) or chronic diarrhoeal illness (e.g. irritable bowel syndrome or inflammatory bowel disease, unless they are in remission for at least 3 months prior to enrolment). * Current use or planned use of an investigational drug within 3 months of enrolment. * Presence of significant immunosuppression, including but not limited to: use of monoclonal antibody, use of prolonged steroids equivalent to prednisolone dose of ≥20mg/day for ≥28 days, solid organ transplantation, bone marrow transplantation, HIV infection with CD4 count of ≤200, bone marrow transplant, ongoing chemotherapy or radiation therapy, and congenital immunodeficiency. * Oropharyngeal dysphagia, significant oesophageal dysphagia, or other inability to swallow. * History of surgery altering gastrointestinal anatomy (e.g. colostomy, colectomy). * Ileus or small bowel obstruction. * Risk of aspiration. * History of gastroparesis. * Severe food allergy (anaphylaxis or anaphylactoid reaction). * Adverse event attributable to previous FMT. * Those who are pregnant or plan to be pregnant within 3 months of enrolment. * Those who are breastfeeding or plan to breastfeed during the trial. * Life expectancy \<3 months.